tetano
Editor, Senior Moderator
Age Ageing
. 2024 Jul 2;53(7):afae145.
doi: 10.1093/ageing/afae145. Reduced risk for Omicron SARS-CoV-2 infection observed in older adults with hybrid immunity
Scott J C Pallett[SUP] 1 2 [/SUP], Jospeh Heskin[SUP] 2 [/SUP], Fergus Keating[SUP] 3 [/SUP], Jeremy Tuck[SUP] 3 4 [/SUP], Andrea Mazzella[SUP] 5 [/SUP], Paul Randell[SUP] 5 [/SUP], Micahel Rayment[SUP] 2 [/SUP], Rachael Jones[SUP] 2 [/SUP], Nabeela Mughal[SUP] 2 6 [/SUP], Gary W Davies[SUP] 2 [/SUP], Matthew K O'Shea[SUP] 1 7 [/SUP], Luke S P Moore[SUP] 2 6 8 [/SUP]
Affiliations
Background: Hybrid SARS-CoV-2 immunity may provide longer duration protection against severe SARS-CoV-2 infection and hospitalisation than purely vaccine-derived immunity. Older adults represent a high-risk group for severe disease, yet available data is skewed towards younger adults.
Methods: A prospective longitudinal study at a large London long-term care facility (LTCF) was conducted from March 2020 to April 2022 to assess the effect of hybrid versus vaccine-only immunity on SARS-CoV-2 infection in older adults during Omicron variant dominance. Hybrid immunity was assessed by a combination of SARS-CoV-2 polymerase chain reaction testing weekly (asymptomatic screening) and as required (symptomatic testing), as well as serial SARS-CoV-2 serology.
Results: 280 participants (median age 82 yrs, IQR 76-88 yrs; 95.4% male) were followed up. 168/280 (60%) had evidence of hybrid immunity prior to the Omicron variant wave. Participants with hybrid immunity had substantially lower odds of acquiring COVID-19 infection during the Omicron wave compared to those with vaccine-only immunity (unadjusted odds ratio 0.26, 95% CI 0.14-0.47, chi-squared P < .0001). Participants with hybrid immunity had an odds ratio of 0.40 (0.19-0.79) for asymptomatic infection and 0.15 (0.06-0.34) for symptomatic infection (Likelihood ratio test, P < .0001).
Discussion: Our data highlight potential opportunities to target ongoing booster vaccination campaigns for those most at risk of severe infection. Reporting of data in older adults will be of particular value to examine the effect of hybrid immunity as new variants continue to emerge and vaccination strategies evolve.
Keywords: COVID-19; ageing health; immunisation; neutralisation; older people; seroconversion.
. 2024 Jul 2;53(7):afae145.
doi: 10.1093/ageing/afae145. Reduced risk for Omicron SARS-CoV-2 infection observed in older adults with hybrid immunity
Scott J C Pallett[SUP] 1 2 [/SUP], Jospeh Heskin[SUP] 2 [/SUP], Fergus Keating[SUP] 3 [/SUP], Jeremy Tuck[SUP] 3 4 [/SUP], Andrea Mazzella[SUP] 5 [/SUP], Paul Randell[SUP] 5 [/SUP], Micahel Rayment[SUP] 2 [/SUP], Rachael Jones[SUP] 2 [/SUP], Nabeela Mughal[SUP] 2 6 [/SUP], Gary W Davies[SUP] 2 [/SUP], Matthew K O'Shea[SUP] 1 7 [/SUP], Luke S P Moore[SUP] 2 6 8 [/SUP]
Affiliations
- PMID: 39003235
- DOI: 10.1093/ageing/afae145
Background: Hybrid SARS-CoV-2 immunity may provide longer duration protection against severe SARS-CoV-2 infection and hospitalisation than purely vaccine-derived immunity. Older adults represent a high-risk group for severe disease, yet available data is skewed towards younger adults.
Methods: A prospective longitudinal study at a large London long-term care facility (LTCF) was conducted from March 2020 to April 2022 to assess the effect of hybrid versus vaccine-only immunity on SARS-CoV-2 infection in older adults during Omicron variant dominance. Hybrid immunity was assessed by a combination of SARS-CoV-2 polymerase chain reaction testing weekly (asymptomatic screening) and as required (symptomatic testing), as well as serial SARS-CoV-2 serology.
Results: 280 participants (median age 82 yrs, IQR 76-88 yrs; 95.4% male) were followed up. 168/280 (60%) had evidence of hybrid immunity prior to the Omicron variant wave. Participants with hybrid immunity had substantially lower odds of acquiring COVID-19 infection during the Omicron wave compared to those with vaccine-only immunity (unadjusted odds ratio 0.26, 95% CI 0.14-0.47, chi-squared P < .0001). Participants with hybrid immunity had an odds ratio of 0.40 (0.19-0.79) for asymptomatic infection and 0.15 (0.06-0.34) for symptomatic infection (Likelihood ratio test, P < .0001).
Discussion: Our data highlight potential opportunities to target ongoing booster vaccination campaigns for those most at risk of severe infection. Reporting of data in older adults will be of particular value to examine the effect of hybrid immunity as new variants continue to emerge and vaccination strategies evolve.
Keywords: COVID-19; ageing health; immunisation; neutralisation; older people; seroconversion.